Dynavax reports updated data for TLR9 agonist combo

Dynavax Technologies Corp. (NASDAQ:DVAX) reported updated response data from the Phase Ib/II MEL-01 (KEYNOTE-184) trial evaluating its SD-101 plus PD-1 inhibitor Keytruda pembrolizumab to treat unresectable stage

Read the full 277 word article

User Sign In